Efficacy and tolerability of a local acting antiseptic agent in the treatment of vaginal dysbiosis during pregnancy

Archives of Gynecology and Obstetrics

Volumn 283, Issue 3, 2011, Pages 585-590

  Briese, Volker ^a   Neumann, Gerd ^b   Waldschläger, Juliane ^a   May, Theodor W ^c   Siebert, Jörg ^d   Gerber, Bernd ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

^c GBP   (Germany)

^d SCHÜLKE AND MAYR GMBH   (Germany)

Author keywords

Octenidine hydrochloride; pH measurement; Preterm birth; Prevention; Vaginal infection

Indexed keywords

2 PHENOXYETHANOL; ANTIINFECTIVE AGENT; ERYTHROMYCIN; LONG ACTING DRUG; OCTENIDINE; OCTENISEPT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIRTH WEIGHT; CONTROLLED CLINICAL TRIAL; DISEASE RESISTANCE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; OUTCOME ASSESSMENT; PH MEASUREMENT; PREGNANT WOMAN; PREMATURITY; SELF EVALUATION; SYMPTOM; TREATMENT DURATION; UREAPLASMA INFECTION; VAGINA DISEASE; VAGINAL DYSBIOSIS; VAGINITIS;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ETHYLENE GLYCOLS; FEMALE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951725488     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-010-1414-4     Document Type: Article

References (26)

1. Raio L (2002) Screeninguntersuchungen auf eine drohende Frühgeburt. Gynäkologe 3:661-662
2. Saling E (2008) Strategien zur Frühgeburtsprävention. In: Hopp H (ed) Kontroversen in der Geburtsmedizin. Akademos Verlag, Hamburg
3. Nygren P, Fu R, Freeman M, Bougatsos C, Klebanoff M, Guise JM (2008) Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the US Preventive Service Task force. Ann Int Med 148:220-233 (Pubitemid 351665509)
4. Usta IM, Nassar AH (2008) Advanced maternal age. Part I: obstetric complications. Am J Perinatol 25:521-534
5. Ryckman KK, Simhan HN, Krohn MA, Williams SM (2009) Cervical cytokine network patterns during pregnancy: the role of bacterial vaginosis and geographic ancestry. J Reprod Immunol 79(2):174-182
6. Xu J, Holzman CB, Arvidson CG, Chung H, Goepfert AR (2008) Midpregnancy vaginal fluid defensins, bacterial vaginosis, and risk of preterm delivery. Obstet Gynecol 112:524-531
7. Simhan HN, Krohn MA (2009) First-trimester cervical inflammatory milieu and subsequent early preterm birth. Am J Obstet Gynecol 200(4):377.e1-377.e4
8. Martius J, Hoyme UB; AG Infektiologie der DGGG (2006) Bakterielle Vaginose in Gynäkologie und Geburtshilfe. AWMF 015/028 guideline of the German Society of gynecology and obstetrics (Dt Ges f Gynäkologie und Geburtshilfe/DGGG), pp 1-6
9. Kekki M, Kurki T, Pelkonen J, Kurkinen-Räty M, Cacciatore B, Paavonen J (2001) Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol 97:643-648
10. Friese K, Neumann G, Siebert J, Harke HP, Kirschner W (2000) Vergleich zweier lokaler Antiseptika in der klinischen Anwendung bei bakteriell bedingten Vaginalinfektionen. Geburtsh Frauenheilk 60:308-313 (Pubitemid 30350494)
11. Friese K, Neumann G, Siebert J (2002) Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 268(3):194-197
12. Neumann G (2005) Infektionen und Infektionskrankheiten. In: Rath W, Friese K (eds) Erkrankungen in der Schwangerschaft. Georg Thieme, Stuttgart
13. Mendling W (2006) Vaginose, vaginitis, zervizitis und salpingitis, 2nd edn. Springer, Heidelberg
14. Petersen EE (2003) Infektionen in Gynäkologie und Geburtshilfe, 4th edn. Georg Thieme, Stuttgart
15. Saling E, Schreiber M (2005) Laktobazillen-Schutzsystem bei Schwangeren - effiziente Vermeidung von Frühgeburten durch Früherkennung von Störungen. Z Geburtshilfe Neonatol 209:119-127
16. Falagas ME, Betsi GI, Athanasiou S (2007) Probiotics for the treatment of women with bacterial vaginosis. Eur J Clin Mikrobiol Infect Dis 13:657-664 (Pubitemid 46909341)
17. Saling E, Al-Taie T, Lüthje J (1999) Frühgeburtenvermeidung- sprogramm, Zusammenarbeit zwischen Arzt, Hebamme und Patientin. Gynäkologe 32:39-45 (Pubitemid 29179581)
18. Hoyme UB, Möller U, Saling E (2003) Aktuelle Aspekte der Thüringer Frühgeburtenvermeidungsaktion 2002. Zentralbl Gynakol 125:107-111
19. Msuya SE, Urivo J, Hussain A, Mbizvo EM, Jeausson S, Sam NE, Stray-Pedersen B (2009) Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. Reprod Health 6(1):4
20. Bailey DM, DeGrazia CG, Hoff SJ, Schulenberg PL, O'Connor JR, Paris DA, Slee AM (1984) Bispyridinamines: a new class of topical antimicrobial agents as inhibitors of dental plaque. J Med Chem 27:1457-1464 (Pubitemid 15200568)
21. Sedlock DM, Bailey DM (1985) Microbicidal activity of octenidine hydrochloride, a new alkanediylbis[pyridine] germicidal agent. Antimicrob Agents Chemother 28(6):786-790 (Pubitemid 16196915)
22. Ghannoum MA, Elteen KA, Ellabib M, Whittaker PA (1990) Antimycotic effects of octenidine and pirtenidine. J Antimicrob Chemother 25(2):237-245 (Pubitemid 20085804)
23. Neumann G (1998) Antiseptika in der therapeutischen Anwendung. Prakt Gynakol 3:223-226
24. Kramer A, Müller G (2008) Octenidine dihydrochloride. In: Kramer A, Assadian O (eds) Wallhäußers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung. Thieme, Stuttgart
25. Goroncy-Bermes P (1998) Investigation into the efficacy of disinfectants against MRSA and VRE. Zentbl Hyg Umweltmed 201:297-309
26. Weissenbacher ER, Klemm A, Baumgartner L, Wachter I, Kassens E, Siebert J, Harke HP (1997) Octenisept®: study of transplacental passage in an in vitro perfusion model with human placenta (in german). Int J Exp Clin Chemother 10(4); suppl. 1